The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial.
D. Malka
Honoraria - Amgen
Research Funding - Amgen
S. Gourgou-Bourgade
No relevant relationships to disclose
J. Emile
No relevant relationships to disclose
P. Laurent-Puig
Honoraria - Amgen
J. Taïeb
Honoraria - Amgen
Research Funding - Amgen